Home › Compare › ICPT vs BTI

ICPT vs BTI: Dividend Comparison 2026

ICPT yields 10.53% · BTI yields 5.40%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ICPT wins by $2.3K in total portfolio value
10 years
ICPT
ICPT
● Live price
10.53%
Share price
$19.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$40.1K
Annual income
$2,037.15
Full ICPT calculator →
BTI
BTI
● Live price
5.40%
Share price
$58.26
Annual div
$3.15
5Y div CAGR
11.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$37.8K
Annual income
$2,802.29
Full BTI calculator →

Portfolio growth — ICPT vs BTI

📍 ICPT pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodICPTBTI
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ICPT + BTI cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
ICPT pays
BTI pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ICPT
Annual income on $10K today (after 15% tax)
$894.74/yr
After 10yr DRIP, annual income (after tax)
$1,731.58/yr
BTI
Annual income on $10K today (after 15% tax)
$459.05/yr
After 10yr DRIP, annual income (after tax)
$2,381.95/yr
At 15% tax rate, BTI beats the other by $650.37/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ICPT + BTI for your $10,000?

ICPT: 50%BTI: 50%
100% BTI50/50100% ICPT
Portfolio after 10yr
$39.0K
Annual income
$2,419.71/yr
Blended yield
6.21%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ICPT right now

ICPT
Analyst Ratings
16
Buy
19
Hold
5
Sell
Consensus: Hold
Price Target
$22.11
+16.4% upside vs current
Range: $10.00 — $44.00
Altman Z
-5.0
Piotroski
3/9
BTI
Analyst Ratings
12
Buy
4
Hold
2
Sell
Consensus: Buy
Price Target
$40.00
-31.3% upside vs current
Range: $40.00 — $40.00
Altman Z
2.1
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ICPT buys
0
BTI buys
0
No recent congressional trades found for ICPT or BTI in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricICPTBTI
Forward yield10.53% ✓5.40%
Annual dividend / share$2.00$3.15 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%11.3% ✓
Portfolio after 10y$40.1K ✓$37.8K
Annual income after 10y$2,037.15$2,802.29 ✓
Total dividends collected$15.4K ✓$14.4K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusHoldBuy
Analyst price target$22.11$40.00 ✓

Year-by-year: ICPT vs BTI ($10,000, DRIP)

YearICPT PortfolioICPT Income/yrBTI PortfolioBTI Income/yrGap
1← crossover$11,753$1,052.63$11,301$601.08+$452.00 → ICPT
2$13,732$1,156.19$12,799$706.58+$933.00 → ICPT
3$15,955$1,262.49$14,527$832.38+$1.4K → ICPT
4$18,443$1,370.97$16,527$982.75+$1.9K → ICPT
5$21,215$1,481.06$18,846$1,162.95+$2.4K → ICPT
6$24,292$1,592.22$21,545$1,379.49+$2.7K → ICPT
7$27,697$1,703.90$24,694$1,640.41+$3.0K → ICPT
8$31,451$1,815.59$28,378$1,955.69+$3.1K → ICPT
9$35,580$1,926.82$32,702$2,337.79+$2.9K → ICPT
10$40,107$2,037.15$37,794$2,802.29+$2.3K → ICPT

ICPT vs BTI: Complete Analysis 2026

ICPT — Stock

Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis; and other product candidates in various stages of clinical and preclinical development. The company has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. It markets its products through an internal commercial organization and third-party distributors. The company was incorporated in 2002 and is headquartered in New York, New York.

Full ICPT Calculator →

BTI — Consumer Staples

British American Tobacco p.l.c. provides tobacco and nicotine products to consumers in the Americas, Europe, the Asia-Pacific, the Middle East, Africa, and the United States. It offers vapour, heated, and modern oral nicotine products; combustible cigarettes; and traditional oral products, such as snus and moist snuff. The company provides its products under the Vuse, glo, Velo, Grizzly, Kodiak, Dunhill, Kent, Lucky Strike, Pall Mall, Rothmans, Newport, Natural American Spirit, and Camel brands. The company distributes its products to retail outlets. British American Tobacco p.l.c. was founded in 1902 and is based in London, the United Kingdom.

Full BTI Calculator →
📬

Get this ICPT vs BTI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ICPT vs SCHDICPT vs JEPIICPT vs OICPT vs KOICPT vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.